Background: NADPH oxidases (Nox) is a major enzyme system contributing to oxidative stress, which plays an important role in the pathogenesis of diabetic kidney disease (DKD). We have shown an elevation of renal Nox1, Nox2, and Nox4 in diabetic mice. APX-115, a pan-Nox inhibitor, attenuated the progression of DKD in mice. As the standard diabetic mice cannot fully mimic human DKD, the present study was aimed to show the dose-dependent effect and to provide a confirmatory evidence of APX-115 in attenuating DKD in diabetic rats. Method: Type 1 diabetes was induced by a single 60 mg/kg intraperitoneal injection of streptozotocin in Sprague-Dawley rats. 0.5, 5, or 30 mg APX-115/kg/day or losartan 1 mg/kg/day were administered orally to diabetic rats for 8 weeks. Results: APX-115 treatment showed an improvement in kidney function and tubular and podocyte -injury, as well as attenuation of inflammation, fibrosis, and oxidative stress as much as losartan, a comparative drug and mainstay treatment in DKD. Therapeutic effect of APX-115 was exhibited in a dose-dependent manner; a dose of 30 mg/kg displayed a superior efficacy. Conclusion: This finding verified the pre-clinical data of APX-115 in protecting against DKD, which is important to bring APX-115 toward the next stage of drug development.

Keywords:
Diabetic kidney disease, pan-NADPH oxidases inhibitor, APX-115, NADPH oxidases, Oxidative stress
1.
Gross JL, De Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T: Diabetic Nephropathy: diagnosis, prevention, and treatment. Diabetes Care 2005; 28: 176–188.
2.
Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW; American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention: Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension 2003; 42: 1050–1065.
3.
Park CW: Diabetic kidney disease: from epidemiology to clinical perspectives. Diabetes Metab J 2014; 38: 252–260.
4.
Fernandez-Fernandez B, Ortiz A, Gomez-Guerrero C, Egido J: Therapeutic approaches to diabetic nephropathy – beyond the RAS. Nat Rev Nephrol 2014; 10: 325–346.
5.
Breyer MD, Susztak K: The next generation of therapeutics for chronic kidney disease. Nat Rev Drug Discov 2016; 15: 568–588.
6.
Ha H, Lee HB: Reactive oxygen species and matrix remodeling in diabetic kidney. J Am Soc of Nephrol 2003; 14: 246S–249S.
7.
Ha H, Hwang IA, Park JH, Lee HB: Role of reactive oxygen species in the pathogenesis of diabetic nephropathy. Diabetes Res Clin Pract 2008; 82(suppl 1):S42–S45.
8.
Singh DK, Winocour P, Farrington K: Oxidative stress in early diabetic nephropathy: fueling the fire. Nat Rev Endocrinol 2011; 7: 176–184.
9.
Forbes JM, Coughlan MT, Cooper ME: Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes 2008; 57: 1446–1454.
10.
Jha JC, Banal C, Chow BS, Cooper ME, Jandeleit-Dahm K: Diabetes and kidney disease: role of oxidative stress. Antioxid Redox Signal 2016; 25: 657–684.
11.
Gill PS, Wilcox CS: NADPH oxidases in the kidney. Antioxid Redox Signal 2006; 8: 1597–1607.
12.
Gorin Y, Block K, Hernandez J, Bhandari B, Wagner B, Barnes JL, Abboud HE: Nox4 NAD(P)H oxidase mediates hypertrophy and fibronectin expression in the diabetic kidney. J Biol Chem 2005; 280: 39616–39626.
13.
Jha JC, Gray SP, Barit D, Okabe J, El-Osta A, Namikoshi T, Thallas-Bonke V, Wingler K, Szyndralewiez C, Heitz F, Touyz RM, Cooper ME, Schmidt HH, Jandeleit-Dahm KA: Genetic targeting or pharmacologic inhibition of NADPH oxidase Nox4 provides renoprotection in long-term diabetic nephropathy. J Am Soc Nephrol 2014; 25: 1237–1254.
14.
Gorin Y, Cavaglieri RC, Khazim K, Lee DY, Bruno F, Thakur S, Fanti P, Szyndralewiez C, Barnes JL, Block K, Abboud HE: Targeting NADPH oxidase with a novel dual Nox1/Nox4 inhibitor attenuates renal pathology in type 1 diabetes. Am J Physiol Renal Physiol 2015; 308:F1276–F1287.
15.
Sedeek M, Gutsol A, Montezano AC, Burger D, Nguyen Dinh Cat A, Kennedy CR, Burns KD, Cooper ME, Jandeleit-Dahm K, Page P, Szyndralewiez C, Heitz F, Hebert RL, Touyz RM: Renoprotective effects of a novel Nox1/4 inhibitor in a mouse model of Type 2 diabetes. Clin Sci (Lond) 2013; 124: 191–202.
16.
You YH, Okada S, Ly S, Jandeleit-Dahm K, Barit D, Namikoshi T, Sharma K: Role of Nox2 in diabetic kidney disease. Am J Physiol Renal Physiol 2013; 304:F840–F848.
17.
Cha JJ, Min HS, Kim KT, Kim JE, Ghee JY, Kim HW, Lee JE, Han JY, Lee G, Ha HJ, Bae YS, Lee SR, Moon SH, Lee SC, Kim G, Kang YS, Cha DR: APX-115, a first-in-class pan-NADPH oxidase (Nox) inhibitor, protects db/db mice from renal injury. Lab Invest 2017; 97: 419–431.
18.
Kwon G, Uddin MJ, Lee G, Jiang S, Cho A, Lee JH, Lee SR, Bae YS, Moon SH, Lee SJ, Cha DR, Ha H: A novel pan-Nox inhibitor, APX-115, protects kidney injury in streptozotocin-induced diabetic mice: possible role of peroxisomal and mitochondrial biogenesis. Oncotarget 2017; 8: 43.
19.
Azushima K, Gurley SB, Coffman TM: Modelling diabetic nephropathy in mice. Nat Rev Nephrol 2018; 14: 48–56.
20.
Sakai C, Iwano S, Yamazaki Y, Ando A, Nakane F, Kouno M, Yamazaki H, Miyamoto Y: Species differences in the pharmacokinetic parameters of cytochrome p450 probe substrates between experimental animals, such as mice, rats, dogs, monkeys, and microminipigs, and humans. J Drug Metab Toxicol 2015; 5: 173.
21.
Joo JH, Huh JE, Lee JH, Park DR, Lee Y, Lee SG, Choi S, Lee HJ, Song SW, Jeong Y, Goo JI, Choi Y, Baek HK, Yi SS, Park SJ, Lee JE, Ku SK, Lee WJ, Lee KI, Lee SY, Bae YS: A novel pyrazole derivative protects from ovariectomy-induced osteoporosis through the inhibition of NADPH oxidase. Sci Rep 2016; 6: 22389.
22.
Hwang I, Lee J, Huh JY, Park J, Lee HB, Ho YS, Ha H: Catalase deficiency accelerates diabetic renal injury through peroxisomal dysfunction. Diabetes 2012; 61: 728–738.
23.
Lane PH, Steffes MW, Mauer SM: Estimation of glomerular volume: a comparison of four methods. Kidney Int 1992; 41: 1085–1089.
24.
Rangan GK, Tesch GH: Quantification of renal pathology by image analysis. Nephrology 2007; 12: 553–558.
25.
Drummond GR, Selemidis S, Griendling KK, Sobey CG: Combating oxidative stress in vascular disease: NADPH oxidases as therapeutic targets. Nat Rev Drug Discov 2011; 10: 453–471.
26.
Holterman CE, Thibodeau JF, Towaij C, Gutsol A, Montezano AC, Parks RJ, Cooper ME, Touyz RM, Kennedy CR: Nephropathy and elevated BP in mice with podocyte-specific NADPH oxidase 5 expression. J Am Soc Nephrol 2014; 25: 784–797.
27.
Jha JC, Banal C, Okabe J, Gray SP, Hettige T, Chow BSM, Thallas-Bonke V, De Vos L, Holterman CE, Coughlan MT, Power DA, Skene A, Ekinci EI, Cooper ME, Touyz RM, Kennedy CR, Jandeleit-Dahm K: NADPH oxidase Nox5 accelerates renal injury in diabetic nephropathy. Diabetes 2017; 66: 2691–2703.
28.
Gray SP, Di Marco E, Okabe J, Szyndralewiez C, Heitz F, Montezano AC, de Haan JB, Koulis C, El-Osta A, Andrews KL, Chin-Dusting JP, Touyz RM, Wingler K, Cooper ME, Schmidt HH, Jandeleit-Dahm KA: NADPH oxidase 1 plays a key role in diabetes mellitus-accelerated atherosclerosis. Circulation 2013; 127: 1888–1902.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.